EGFR-TKI靶向治疗联合养阴解毒颗粒对EGFR基因突变型晚期肺腺癌疾病控制率、肿瘤标志物、不良反应的影响

Effects of EGFR-TKI Targeted Therapy Combined with Yangyin Jiedu Granules on Disease Control Rate,Tumor Markers and Adverse Reactions in Patients with EGFR Gene-mutant Advanced Lung Adenocarcinoma

目的:评价EGFR-TKI靶向治疗联合养阴解毒颗粒治疗表皮生长因子受体(Epidermalgrowthfactorreceptor,EGFR)基因突变型晚期肺腺癌患者的疗效,观察其疾病控制率、肿瘤标志物及不良反应。方法 :选取2019年6月—2021年2月河南省开封市通许县中医院收治的82例EGFR基因突变型晚期肺腺癌患者,按照治疗方法不同分为观察组41例、对照组41例,其中对照组给予养阴解毒颗粒,观察组给予EGFR-TKI靶向治疗+养阴解毒颗粒,治疗4个疗程,对比两组总有效率、生活质量量表(Quality of life questionnaire,QLQ-30)评分、肿瘤标志物[癌抗原125(Cancer antigen125,CA125)、癌胚抗原(Carcinoem bryonicantigen,CEA)、细胞角蛋白、血管内皮生长因子(Vascular epithahal growth factor,VEGF)、癌抗原242(Cancer antigen242,CA242)]水平及不良反应发生率。结果:观察组总有效率46.34%(19/41)、疾病控制率75.61%(10/41)显著高于对照组24.39%(31/41)、48.78%(20/41)(P<0.05);治疗4个疗程后两组QLQ-30评分均较治疗前升高,观察组血清QLQ-30评分高于对照组(P<0.05);治疗4个疗程观察组血清CEA、VEGF、CA125、CA242、细胞角蛋白水平低于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论 :EGFR-TKI靶向治疗+养阴解毒颗粒治疗EGFR基因突变型晚期肺腺癌患者可有效提高总有效率及疾病控制率,调节血清肿瘤标志物水平,提高生活质量,且具有一定安全性。

Objective:To evaluate the curative effect of EGFR-TKI targeted therapy combined with Yangyin Jiedu Granules in the treatment of advanced lung adenocarcinoma patients with epidermal growth factor receptor(EGFR)mutation,and to observe the disease control rate,tumor markers and adverse reactions.Methods:From June 2019 to February 2021,82 patients with EGFR gene mutation advanced lung adenocarcinoma admitted to Tongxu County Hospital of Traditional Chinese Medicine,Kaifeng City,Henan Province were selected and divided into observation group(41 cases)and control group(41 cases)according to different treatment methods.The control group was given Yangyin Jiedu Granules,and the observation group was given EGFR-TKI targeted therapy+Yangyin Jiedu Granules for 4 courses of treatment.The total effective rate and quality of life scale(Quality of life questionnaire,QLQ-30)were compared between the two groups.Score,tumor markers[cancer antigen 125(Cancer antigen125,CA125),carcinoem bryonicantigen(CEA),cytokeratin,vascular endothelial growth factor(Vascular epithahal growth factor,VEGF),cancer antigen 242(Cancer antigen242,CA242)]levels and the incidence of adverse reactions.Results:The total effective rate of the observation group was 46.34%(19/41),and the disease control rate was 75.61%(10/41),which were significantly higher than those of the control group 24.39%(31/41),48.78%(20/41)(P<0.05);After 4 courses of treatment,the QLQ-30 scores of both groups were higher than those before treatment,and the serum QLQ-30 scores of the observation group were higher than those of the control group(P<0.05);after 4 courses of treatment,serum CEA,VEGF,CA125,CA242,The level of cytokeratin was lower than that of the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:EGFR-TKI targeted therapy+Yangyin Jiedu Granules in the treatment of patients with EGFR gene mutation advanced lung adenocarcinoma can effectively improve the total effective rate and disease control rate,regulate the level of serum tumor markers,improve the quality of life,and has certain safety.